Breakthrough innovative technologies offer solutions that are simpler, more convenient, and cheaper. They disrupt the market and displace older players. Today, there are two key trends in healthcare: the first is the evolution of existing and very expensive technologies, often requiring highly qualified specialists to implement them. The second is a revolution of breakthrough innovations based on new physical principles and solutions. For example, simpler reconstructive heart vessel surgery can replace a dangerous and prolonged bypass operation. The use of portable devices for self-monitoring of blood sugar reduces the need for visits to the endocrinologist, while digital technology will give patients the opportunity to manage their health. Creating a balance between expensive and breakthrough technologies allows for the accelerated development of the industry, and this task is the responsibility of the organizers of the public health system. What breakthrough technologies are already having an impact on healthcare today? What breakthrough healthcare technologies will businesses be able to offer tomorrow? What system should the state use to support scientific research? What are the barriers to the introduction of breakthrough technologies, and how can they be overcome? How will artificial intelligence change the roles of the doctor, nurse, and patient? How can an effective relationship between business, regulators, and consumers be established?
Moderator Guzel Ulumbekova,
President of the Board, Association of Medical Societies for Quality of Medical Care and Medical Education; Head, Higher School of Healthcare Organization and Management
Guzel Ulumbekova
President of the Board, Association of Medical Societies for Quality of Medical Care and Medical Education; Head, Higher School of Healthcare Organization and Management
Head of the Higher School of Healthcare Organization and Management, Chairman of the Board of the Association of Medical Communities for the Quality of Medical Care and Medical Education. Chairman of the Commission on Continuing Education of the National Medical Chamber, member of the Coordinating Council of the Ministry of Healthcare of Russia for Development of Continuing Medical and Pharmaceutical Education, member of the Board and Executive Secretary of the Russian Society for Healthcare Organization and Public Health. Since 2003, she has been heavily involved in expert activities on healthcare organization at the Civic Chamber and the Chamber of Commerce and Industry of the Russian Federation, the State Duma Committee on Healthcare, the Strategic Research Centre of the Ministry of Economic Development of the Russian Federation, the WHO Council for Evidence-Based Medicine, etc. Guzel Ulumbekova is the author of the books Russia’s Healthcare. What Needs to Be Done (2010) and Russia’s Healthcare. What Needs to Be Done-2 (2015) and a textbook for medical schools Public Health and Healthcare (2011); she is a contributor to and a member of the editorial board of the national guide Public Health and Healthcare (2013).
Panellists Kostas Varlas,
Regional European Director, Diagnostics Division (ADD), Abbott Laboratories Zeger Vercouteren,
Vice President for Government Affairs and Policy, Europe, Middle East and Africa (EMEA), Johnson & Johnson Anthony Wong,
Regional Vice President, Russia, Ukraine and CIS, AbbVie Trevor Gunn,
Vice President for International Relations, Medtronic
Petr Glybochko,
Rector, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation Alexander Ivlev,
Country Managing Partner for Russia, EY Dmitry Morozov,
General Director, BIOCAD Veronika Skvortsova,
Minister of Healthcare of the Russian Federation Arkadiy Stolpner,
Chairman of the Board of Directors, DTC IIBS Sergey Tsyb,
Deputy Minister of Industry and Trade of the Russian Federation Evgeniy Shlyakhto,
Director General, Almazov National Medical Research Centre; President, All-Russian Non-Governmental Organization "Russian Society of Cardiology"
Kostas Varlas
Regional European Director, Diagnostics Division (ADD), Abbott Laboratories
Konstantinos Varlas, Managing Director for diagnostics division Europe East, joined Abbott in 2001. In his current role, Konstantinos шы responsible for the implementation of effective diagnostic solutions of Abbott in Russia, Israel, Greece and other Eastern European countries. Konstantinos has been working in the healthcare industry for more than 20 years involved in several projects of Centralization and Private Public Partnership with different European Governments. He has been involved in strategic projects in China, focused in Infectious Diseases Diagnosis and Monitoring In 2000 he was advisor of the Minister of Health in Greece changing the procurement legislation and establishing new administrative structure in Health Care System Konstantinos hold PhD in Neuroscience from McGill University focused in Declarative Memory.
Zeger Vercouteren
Vice President for Government Affairs and Policy, Europe, Middle East and Africa (EMEA), Johnson & Johnson
Zeger Vercouteren is Vice President Government Affairs & Policy, Johnson & Johnson EMEA, responsible for developing / leading the Enterprise & Sector strategies, talent development and resource allocation and as such serves on the WW Corporate Office’s GA&P Global Leadership Team. He has a long-standing European/International LifeSciences track record, led GA&P Medical Devices EMEA, served on the Management Board Global Surgery Group EMEA. Prior to Johnson & Johnson, Zeger headed the Baxter Europe’s European GA&P, covering the interests of the devices/biotech/pharm/vaccines sectors and was Eucomed’s Deputy Director General, having joined from a business services background. Zeger received the ‘Corporate Public Affairs Professional of the Year’ EPAD Award 2008, is a Johnson & Johnson Trust Board member and Board member of The European Policy Center and AmCham EU, where he was also elected as Chair of the Brexit Task Force. Zeger has an honors law degree from the FNDP-Namur/KULeuven/UC-Barcelona Universities; honors Business Administration Master's Degree from the Solvay Business School/ULB. He speaks Dutch, French, English, Spanish, Catalan & understands German.
Anthony Wong
Regional Vice President, Russia, Ukraine and CIS, AbbVie
Tony Wong leads AbbVie business in Russia and the CIS countries as the General Manager since March 2013. Previously since the beginning of 2013 Mr. Wong held the position of the General Manager of AbbVie Russia and prior to it, since 2008, was the General Manager of Proprietary Pharmaceutical Division of Abbott in Russia. Tony Wong’s experience in the pharmaceutical industry of exceeds 17 years with previously held positions in Manufacturing, Finance and General Management. Before his roles in Abbott and AbbVie, Mr. Wong served as General Manager for Schering-Plough for eight years and five years as a Senior Manager at PricewaterhouseCoopers in M&A and Strategic Advisory Services in Russia. Tony’s experience includes 16 years of General Management experience for three US based Fortune 500 pharmaceutical companies. For the past four years Tony Wong is a member of Association of International Pharmaceuticals Manufacturers (AIPM) and for the past two years is a Co-Chairman of InPharma Association. Anthony Wong graduated from Columbia University with Degree in Industrial Engineering, and with an MBA in Finance and International Business from New York University.
Trevor Gunn
Vice President for International Relations, Medtronic
На протяжении длительного времени Тревор Ганн занимал должность директора службы деловой информации Министерства торговли по новым независимым государствам (BISNIS), отвечающей за предоставление правительству США информации о ведении бизнеса в странах бывшего СССР. Последние 24 года он постоянно работал и продолжает работать внештатным преподавателем в CERES/Высшей школе дипломатической службы Джорджтаунского университета. Награжден серебряной медалью за 20-летнюю службу. Получил степень бакалавра в университете Сан-Франциско. Получил докторскую степень в области международных отношений в Лондонской школе экономики в 1992 году. Работал в Торговой палате Южной Швеции, компании Dover Elevator Corporation (сейчас ThyssenKrupp of Germany), организации International Executive Service Corps, а также в штабе бывшего мэра Сан-Франциско и двух сенаторов США от штата Калифорния. Учредитель и председатель организации USA Healthcare Alliance (USAHA). Входит в Совет по заинтересованным сторонам Государственного департамента США по руководящим принципам корпоративной социальной ответственности ОЭСР; является официальным советником по торговле Управления торгового представительства США (USTR) в системе «Отраслевых консультаций по торговле» правительства США. Г-н Ганн возглавляет Комитет по международным отношениям в Medtech Europe, крупнейшей в Европе торговой ассоциации в области медицинских технологий. Кроме того, он является членом Совета директоров Американо-Российского делового совета, является вице-председателем Исполнительного совета по дипломатии. Входит в Вашингтонский совет по экспорту (Вашингтон, округ Колумбия), группу консультантов Вашингтонского международного делового совета и совет центра гражданских инициатив (Сан-Франциско). Кроме того, является участником «Форума по государственно-частным партнерствам в области мирового здравоохранения» Национальной академии наук/Института медицины (IOM) и членом Окружного совета по экспорту Министерства торговли США (Вирджиния). Наконец, входит в Консультационный совет Международного института Карлсона бизнес-школы Карлсона при Университете Миннесоты. Тревор Ганн владеет шведским, французским и русским языками. Г-н Ганн, его супруга (Анна) и их трое детей живут в пригороде Мэриленда недалеко от Вашингтона, округ Колумбия.
Petr Glybochko
Rector, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
Alexander Ivlev
Country Managing Partner for Russia, EY
Alexander is the leader of EY Russia. He is actively involved in the work of the Foreign Investment Advisory Council in Russia. At the 2007 World Economic Forum, Alexander was entered in the list of Young Global Leaders, and in 2009 he was included in the top 100 young leaders in the Russian Presidential Reserve. He is vice president of the World Economic Forum's Global Agenda Council on Russia. Alexander is a member of the Expert Council of the Open Innovations Forum, the Executive Committee of the Krasnoyarsk Economic Forum, the Organizing Committee of the St. Petersburg International Economic Forum and the Public Council of the Ministry of Economic Development of the Russian Federation. He leads the National Business Initiative’s road map Improving the quality of the regulatory environment for business. Alexander supervises the Entrepreneur of the Year program in Russia. Alexander has over twenty years of experience in strategic development, client service and government and corporate affairs. He is a graduate of Moscow State Linguistic University (1991) and has an EMBA from the University of Chicago Booth School of Business (2003).
Dmitry Morozov
General Director, BIOCAD
Date of birth: February 1, 1965 Place of birth: Moscow Marital status: Married, with three children Dmitry Morozov is a member of the Council for Development of the Pharmaceutical and Medical Industry attached to the Government of the Russian Federation. He is on the list of the Top 500 reserve management executives under the auspices of the President of the Russian Federation.Dmitry Morozov graduated from the Radio Technology Department of the State Academy of Consumer Services in Moscow. 1997–1998: Studied at the Plekhanov Russian Academy of Economy in Moscow, Department of Finance and Credit. Earned a diploma in Economics. 1998: Successfully completed an MBA programme at the MIRBIS Moscow International Higher School of Business and obtained an MBA in Management. 2004: Studied at the Keio Business School in Japan under a presidential programme. 1993–2002: Vice Chairman of the Management Board, CentroCredit Bank. 2001: Founded CJSC Biocad; currently serves as its President. Biocad manufactures ready-made medicines, pharmaceutical substances and genetic engineering products.
Veronika Skvortsova
Minister of Healthcare of the Russian Federation
Veronika Skvortsova was born in Moscow on November 1, 1960. She graduated from the 2nd Pirogov Moscow State Medical Institute in 1983 and completed a Postgraduate Clinical Residency Programme and an Advanced Postgraduate Programme specializing in neuropathology. In 1994, she qualified as a higher category neurologist. After graduating, she worked for the 2nd Moscow State Medical Institute (the Russian State Medical University since 1991) for 25 years. Veronika Skvortsova became head of one of Russia’s first neurology emergency services at Moscow’s 1st municipal hospital established on the basis of the neurology clinic of the 2nd Moscow State Medical Institute in 1989. In 1989–1995, she served as assistant and, in 1995–1997, as assistant professor at the Neuropathology Department of the Russian State Medical University. She became Head of the Fundamental and Clinical Neurology and Neurosurgery Department in 1997. Veronika Skvortsova was appointed Director of the Russian Stroke Research Institute in 2005. She was Deputy Minister of Healthcare and Social Development from 2008 to 2012. Veronika Skvortsova was appointed Minister of Healthcare by Presidential Executive Order No. 650 of May 21, 2012. She is vice-president and co-founder of the National Stroke Association, director of the World Stroke Organization and secretary general of the European Stroke Council. She is a Doctor of Medicine, Professor, and Corresponding Member of the Russian Academy of Medical Sciences. Veronika Skvortsova is an Honored Scientist of the Russian Federation. She has been awarded an Order of Honour and won the Pirogov Prize and Moscow Government Prize in Medicine. She is the author of more than 400 research papers and holds seven patents for her inventions.
Arkadiy Stolpner
Chairman of the Board of Directors, DTC IIBS
Born March 28, 1958 in Leningrad. In 1982 Graduated Leningrad’s First Medical Institute named after Pavlov with a major in Medicine. Completed a post graduate course in VNIIFK in Leningrad in 1987. In 1990 graduated Shenyang Medical Institute in China with a degree in Oriental Medicine for foreigners. Since 1991 remained on senior staff of various hi-tech retail and R&D companies. Became CEO of LDC MIBS in 2003 and currently oversees all the innovative projects in the company. The list of company’s projects includes: Largest MRI network in Russia. Largest telemedical network. Center for radiosurgery and radiotherapy. World-class athlete in rowing. Married, raised a daughter and two sons.
Sergey Tsyb
Deputy Minister of Industry and Trade of the Russian Federation
Date of birth: 29 April 1968 Place of birth: Obninsk, Kaluga Region Education: Graduated from G.V. Plekhanov Russian Academy of the Economics, PhD in Economics Work history: 1991–2007: Executive positions in various businesses 2007–2008: Director, Chemical Technology Complex and Bio-Engineering Technology Department of the Ministry of Industry and Energy of the Russian Federation 2008–2013: Director, Chemical Technology Complex and Bio-Engineering Technology Department of the Ministry of Industry and Trade of the Russian Federation Since 2013: Deputy Minister of Industry and Trade of the Russian Federation Awards: 2009: Mercy honorary badge from the Ministry of Healthcare and Social Development of the Russian Federation 2011: Honorary Chemist title from the Ministry of Industry and Trade of the Russian Federation 2011: Prize of the Government of the Russian Federation in the field of science and technology for development and implementation of the scientific fundamentals of the national system of chemical product turnover safety 2015: Medal of the Service to the Motherland Order 2nd Degree Civil rank: Full State Councillor of the Russian Federation, 1st Class
Evgeniy Shlyakhto
Director General, Almazov National Medical Research Centre; President, All-Russian Non-Governmental Organization "Russian Society of Cardiology"
Professor Evgeny Shlyakhto, Director General of the Almazov National Medical Research Centre, Academician of the Russian Academy of Science, President of the Russian Society of Cardiology, Fellow of the European Society of Cardiology, the American Heart Association, and the American College of Cardiology. Professor Shlyakhto was born on June 29, 1954 in Pogar, the Bryansk region. He graduated from the Pavlov Medical University in Saint Petersburg in 1977 and became Doctor of Science in Medicine in 1992, Professor in 1994, Honored Russian Scientist in 2004, and Academician of the Russian Academy of Sciences in 2014. Evgeny Shlyakhto has been the Director General of the Almazov National Medical Research Centre since 2001 and the President of the Russian Society of Cardiology since 2011. In 2010, he became a member of the WHO Expert Working Group. The Centre led by Prof. Shlyakhto carries out intensive research in the fields of translational medicine, molecular diagnostics, development of diagnostic tools for personalized treatment, cellular and tissue engineering for therapeutic purposes, creation of biocompatible materials and tissue-engineered constructs designed to create breakthrough medical technologies of fundamental importance for providing high-tech care to patients with cardiovascular, endocrine and blood diseases. The results of research work by Prof. Shlyakhto have been summarized in more than 800 publications, 16 inventions, 2 scientific discoveries, and a number of monographs. Prof. Shlyakhto was a supervisor in 57 PhD and 20 DSc students.. Professor Shlyakhto is a member of the Presidium of the Russian Academy of Science, the Presidential Council for Science and Education, the Regional Health Council under the Federation Council of the Russian Federal Assembly, the Expert Health Council of the Federation Council Committee on Social Policy of the Russian Federal Assembly, Vice President of the National Medical Chamber. Evgeny Shlyakhto is the Editor-in-Chief of the following medical journals: Russian Journal of Cardiology, Translational Medicine, and Journal of Arrhythmology. He also is a member of the international editorial board of the European Heart Journal. Professor Shlyakhto plays an active role in such international committees as the ESC Congress Programme Committee (since 2012) and of the ESC Committee for Practice Guidelines (since 2015). Evgeny Shlyakhto received the Russian Federation Government Prize in science and technology in 2009 and won the Pavlov Award, the prize for scientific and technological achievement in Physiology and Medicine from the Saint Petersburg Government and St. Petersburg Scientific Center of the Russian Academy of Sciences, in 2011. He received an Order of Honour in 2012 and 4th class Order of Merit for the Motherland in 2017.
Front row participants Michael Ball,
Chief Executive Officer, Alcon Elena Brusilova,
President, International Clinic MEDSI Matthias Wernicke,
General Manager, Merck Biopharma Russia and CIS Michael McGannon,
Co-Founder, McGannon Institute of Proactive Health Eyal Mishani,
Head, Cyclotron Radiochemistry Unit, Hadassah Hebrew University Hospital Mikhail Murashko,
Head, Federal Service on Surveillance in Healthcare Irina Panarina,
General Manager, Russia and Eurasia, AstraZeneca
Michael Ball
Chief Executive Officer, Alcon
F. Michael (Mike) Ball was appointed CEO of Alcon in February 2016. He is a member of the Executive Committee of Novartis. Mr. Ball previously served as CEO of Hospira Inc. from 2011 to 2015. Prior to that, he held a number of senior leadership positions at Allergan Inc., including president from 2006 to 2011. Before joining Allergan in 1995, Mr. Ball held roles of increasing responsibility in marketing and sales at Syntex Corporation and Eli Lilly & Co. He began his career in the healthcare industry in 1981. Mr. Ball has served on the boards of several companies based in the United States, including Kythera Biopharmaceuticals Inc. (2013 to 2015), Hospira (2011 to 2015), IntraLase Corp. (2005 to 2006), and sTec Inc. (2000 to 2013). He holds a Bachelor of Science and a Master of Business Administration from Queen’s University in Canada.
Elena Brusilova
President, International Clinic MEDSI
In 1986, she graduated from Second Leningrad Medical Institute. In 2004, she received a degree in International Business Management from Russian Presidential Academy of National Economy. 12.2014 – Present Medsi Group, President 05.2010-12.2014 Bashneft, Vice President for Corporate Communications and GR 11.2007-05.2010 Medsi Group, Vice President for Special Projects and Government Relations 02.2006-10.2007 VTB Insurance, First Deputy CEO 03.2005-02.2006 Rosno, Deputy Head of Department of Insurance for Financial Institutions 06.2001-02.2005 Medical-Technological Holding Company, Head of Department
Matthias Wernicke
General Manager, Merck Biopharma Russia and CIS
Matthias holds a Master’s as well as Doctor’s degree in Economics from Oxford University, UK. Before joining Merck, he was a Partner at McKinsey & Co in Berlin providing consulting services to customers from the pharmaceutical and healthcare industry. Matthias joined Merck in 2014 as a European Head of Market Access & Pricing. From June 2015 to September 2017, Matthias Wernicke was Managing Director of Merck Austria, based in Vienna. In October 2017, Dr.Wernicke was appointed General Manager of Merck Biopharma Russia & CIS.
Michael McGannon
Co-Founder, McGannon Institute of Proactive Health
Dr. McGannon, an American citizen, holds a doctorate in medicine from Georgetown University, and a post-doctoral research fellowship from Stanford University. Dr. McGannon is also a world-renowned specialist in proactive medicine, particularly as it applies to corporate life. His groundbreaking program, Mentoring for Self-Mastery (MSM-24), the newest, most evolved Leadership Health Module at INSEAD, based on Gamified Behavioral Change (GBC). The MSM-24 is an educational and motivational program designed to provide leading managers with a critical “Wake-Up Call”, an opportunity to reflect and take stock of their most important assets: health & sanity. Academic bases: He has led the MSM-24 at business schools (e.g. INSEAD, Cambridge University, CEIBS, IMD, Singapore Institute of Management, Skolkovo, Sberbank Corporate Uni), companies, embassies and organizations worldwide. Publications: 1. The Urban Warrior’s Book of Solutions, Stay Healthy, Fit & Sane in the Business Jungle (2002 by Financial Times), 2. Fit for the Fast Track (2005 by FT Publishing), and 3. The Business Leader’s Health Manual, (2009) 4. My Self-Mastery (2018, Alpina Press, Moscow)
Eyal Mishani
Head, Cyclotron Radiochemistry Unit, Hadassah Hebrew University Hospital
Born in Israel in 1963, married with two children. In 1990, I received my Bachelor’s degree in Chemistry from Tel Aviv University With Distinction. Subsequently, I started direct courses towards Ph.D. studies in the field of Organic Fluorine Chemistry. In 1994, I received my Ph.D. degree With Distinction from Tel Aviv University. From 1994-1996, I completed my post-doctoral fellowship at Washington University, St. Louis, MO, in the field of PET molecular imaging. During my postdoctoral fellowship, I designed the PET/Radiochemistry Laboratory at Hadassah/Hebrew University Hospital in Israel. Beginning of 1997, I returned to Israel to establish the first PET Cyclotron facility in Israel in which I presently serve as Head of the Unit. Upon my return to Israel, I pioneered the production and distribution of FDG which completely transformed the clinical diagnostic approach in this country. In conjunction with the Health Ministry, I established the guidelines for FDG production. In 2012, I was appointed as a full Professor at Hadassah/Hebrew University Hospital. I am a member of the editorial board of Nuclear Medicine and Biology (the official journal of the Society of Radiopharmaceutical Sciences) and I serve as the International Associate Editor of Molecular Imaging and Biology (the official journal of the Society of Molecular Imaging). Recently, I served as the director at large of the International Society of Radiopharmaceutical Sciences (2011-2013). Throughout the ensuing years, I served as reviewer of several journals such as Journal of Medicinal Chemistry, Journal of Nuclear Medicine, Journal of Labeled Compounds and Radiopharmaceuticals, Applied Radiation and Isotopes, etc. My main research aim is to develop molecular imaging methodologies to explore the in–vivo mechanism of various biochemical processes under normal and pathological conditions and translate them into imaging of diseases. In this context, I have pioneered several basic and comprehensive research projects encompassing various fields of nuclear medicine molecular imaging. I have published over 85 scientific papers in peer-reviewed journals and have five patents in the field of imaging protein tyrosine kinases and AR in cancer. Most importantly, the research on imaging EGFR in cancer was a pioneering endeavor from which several research reports have emanated by others throughout the years. In fact, several clinical trials have recently been initiated in Europe and the U.S. principally based on our initial work. Based on our research, I have been invited by reputed journals to contribute three reviews in this field. During the past 12 years, I have served as mentor to seven Ph.D. and to four M.Sc. students in the field of molecular imaging and I have formulated a special course in this particular field at the School of Pharmacy of the Hebrew University. In 2010, I completed the installation of a second Cyclotron and a microPET/CT (the first in Israel) at Hadassah Hospital. In mid-2014, I was appointed to be the Head of the R&D division at Hadassah, the General Director of the Research Fund of the Hadassah Medical Organization (RFHMO) and a board member of Hadassit the technology transfer company of Hadassah. I established the research fund as an independent legal entity and today there are 200 research employees with an income for research projects totaling almost 100M shekels annually.
Mikhail Murashko
Head, Federal Service on Surveillance in Healthcare
Born on January 9, 1967 in Sverdlovsk. 1986-1988 – served in the USSR Army. 1992 – graduated from Ural State Medical Institute. August 1992 – March 1996 – intern; Obstetrician Gynecologist, Komi Republic Hospital in Syktyvkar. March 1996 – November 1996 – Deputy Medical Superintendent for Consulting and Diagnostics, Medical Superintendent, Komi Republic Perinatal Center in Syktyvkar. November 1996 – December 1999 – Medical Superintendent, Komi Republic Medical Group in Syktyvkar. January 2000 – March 2006 - Medical Superintendent, Komi Republic Perinatal Center under Komi Republic Agency of Health Care, Syktyvkar. March 2006 – February 2011 – Minister of Health Care, Komi Republic. February 2011 – June 2012 – Head of Department, Obstetrics and Gynecology Department (offers a course of pediatrics), Kirov State Medical Academy under the Ministry of health Care of the Russian Federation, Syktyvkar. July 2012 – March 2013 – Deputy Head, Federal Service for Health Care Supervision, Moscow. July 2013 – July 2015 – acting Head, Federal Service for Health Care Supervision. July 14, 2015 till present time – Head of the Federal Service for Health Care Supervision (has the title of the Full State 2-nd Class Counsellor of the Russian Federation). 1999 – Doctor of Medicine. 2004 – postgraduate degrees in Obstetrics/Gynecology and Public Health Care Administration. Board certified in Obstetrics/Gynecology and Public Health Care Administration. Editor-in-Chief and Founder, Human Health in the North Journal. Editorial Board Member, Children’s Health Care in the North West Journal.
Irina Panarina
General Manager, Russia and Eurasia, AstraZeneca
Since May 2017 Irina Panarina has been appointed to the position of General Manager of AstraZeneca, Russia and Eurasia. Irina is responsible for AstraZeneca business in Russia & Eurasia Area and she leads AstraZeneca Russia. Irina Panarina has worked for AstraZeneca since 2009. In October 2015 Irina joined the Russian team as Cardiovascular and Metabolic Disease Business Unit Head. Before coming to Russia, Irina Panarina held the position of General Manager at AstraZeneca Ukraine. Prior to joining AstraZeneca Irina held regional roles at GSK Pharma headquarters in London, UK. Irina Panarina has work experience in marketing, product portfolio management, people development. Irina Panarina has degrees from Newcastle University & South Bank University. She also holds MBA degree from INSEAD Business School.
